The largest real-world study ever conducted on prostate cancer in Brazil analyzed data from 670,205 patients treated through the Brazilian Unified Health System (SUS) over a 16-year period, between 2008 and 2023. Published in the Journal of Global Oncology, the study included researchers from the D’Or Institute for Research and Education (IDOR) and investigated patterns of diagnosis, treatment, and health care costs related to the disease across the country. The results revealed significant racial inequalities, including a higher frequency of advanced disease at diagnosis among non-white men and differences in therapeutic investment.
Continue Reading this article here
